Company intelligence / Profile preview

Tan Thanh Holdings Investment

Vietnam

Ownership: Private
Development stage: Other

Overview

Tan Thanh Holdings Investment is a Vietnam-based pharmaceutical company partnering with Oravax Medical to conduct advanced-stage clinical trials and commercialize Oravax’s oral COVID-19 vaccine in Southeast Asia. The vaccine is a virus-like particle (VLP) formulation targeting three SARS-CoV-2 surface proteins, designed for broader variant protection and simplified logistics (no subfreezing storage required)[1][2][4]. The company has secured rights to distribute the vaccine in ASEAN countries following regulatory approval[2][4]. No peer-reviewed clinical results are yet available, as the vaccine is still in early clinical development[2].

Therapeutic areas: Infectious Diseases
Modalities: Vaccine
Industry: Biotech

Partnerships

Oravax MedicalOramed PharmaceuticalsPremas Biotech

Beyond the preview

Go deeper on Tan Thanh Holdings Investment.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tan Thanh Holdings Investment.

Explore the full profile